Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis Academic Article uri icon

Overview

MeSH Major

  • Idiopathic Pulmonary Fibrosis
  • Peptide Hydrolases
  • Severity of Illness Index

abstract

  • A total of 274 patients underwent randomization. There was no significant difference in the adjusted mean change from baseline in the SGRQ total score at week 12 between the nintedanib-plus-sildenafil group and the nintedanib group (-1.28 points and -0.77 points, respectively; P=0.72). A benefit from sildenafil treatment was not observed with regard to dyspnea as measured with the use of the University of California, San Diego, Shortness of Breath Questionnaire. No new safety signals were observed, as compared with previous trials.

publication date

  • November 2018

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1811737

PubMed ID

  • 30220235

Additional Document Info

start page

  • 1722

end page

  • 1731

volume

  • 379

number

  • 18